Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Tela Bio, Inc. TELA

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$80.3M
▲ 15.8% YoY
$-38.8M
$-28.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Its first portfolio of products, the OviTex Reinforced Tissue Matrix, first commercialized in the U.S. in July 2016 and in Europe in February 2019, addresses unmet needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials while minimizing their shortcomings, at a cost-effective price. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, first commercialized in the U.S. in May 2019, addresses unmet needs in plastic and reconstructive surgery. Based on the volume weighted average selling price of its OviTex products, the company estimates the annual U.S. total addressable market opportunity for its OviTex products to be approximately $1.8 billion. As of December 31, 2025, the company had 218 employees worldwide. TELA Bio, Inc. was incorporated on April 17, 2012.

Written from the business description in TELA Bio, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 25 March 2026. Every sentence was checked against that document before publication.

Growth

USD 80.3M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 80.3 · Net income -38.8
30M60M-20M-40M
2017202020232025
Compound annual growth
+24.7%
+34.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +34.5% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−48 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -42.0% · Net -48.4%
-200%-400%
201720212025
ROE
FY2025 · ROE -223.4%
-100%-200%
201720212025
Three returns, three denominators.

Each USD of equity lost 223 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -28.7
-15M-30M
201720212025

Total assetsUSD 81.4M
EquityUSD 6.3M
CashUSD 50.8M
Gross debtUSD 55.7M
Net debtUSD 4.8M
Current ratio4.20×

Net debt stands at 76% of equity.

The 9-year record

9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
TELA, 9-year financial record
Metric 202520242023202220212020201920182017
Revenue $B0.10.10.10.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.0−0.0◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.83−1.33−2.04−2.72−2.30−2.23−17.10−101.41◌
Dividend / sh $◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————
ROE %−223.4−159.9−281.2−257.5−96.3−72.0———
Shares out B0.040.040.020.020.010.010.010.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 2 divergences in 42 reconciliationsAUDITED

Reconciled in 7 of the 9 fiscal years we could check. 2 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 22 checks were skipped: the balance sheet is not tagged before 2018. 11 checks were skipped: EPS is not tagged before 2018. 10 checks were skipped: revenue is not tagged before 2017.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures2 divergent
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017

Share this section

Download image